NCT02349490View on ClinicalTrials.gov

Seraseal for Endoscopic Hemostasis

PHASE4CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

July 31, 2013

Study Completion Date

January 31, 2015

Conditions
Gastrointestinal Hemorrhage
Interventions
DEVICE

Seraseal / Fastact Hemostatic agent (combined activated factors IIa, VIIa, IXa, Xa )

Following endoscopic confirmation of a bleeding, 2,5-5ml of liquid Seraseal / Fastact, is topically applied to the bleeding site via catheter

Trial Locations (4)

1090

Division of Gastroenterology, Medical University of Vienna, Vienna

2030

Rudolfstiftung, Vienna

4020

KH der Elisabethinen Linz, Linz

Unknown

Hannover Medical School, Hanover

All Listed Sponsors
lead

Medical University of Vienna

OTHER

NCT02349490 - Seraseal for Endoscopic Hemostasis | Biotech Hunter | Biotech Hunter